Search details
1.
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
Gynecol Oncol
; 143(1): 27-34, 2016 Oct.
Article
in English
| MEDLINE | ID: mdl-27546885
2.
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 15(8): 799-808, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24950985
3.
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial.
Breast Cancer Res Treat
; 133(3): 1067-75, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-22415477
4.
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 34(22): 2636-43, 2016 08 01.
Article
in English
| MEDLINE | ID: mdl-27298414
5.
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.
Wien Klin Wochenschr
; 122(11-12): 368-79, 2010 Jun.
Article
in English
| MEDLINE | ID: mdl-20549373
Results
1 -
5
de 5
1
Next >
>>